ZA202205149B - Benzylamide derivatives as inhibitors of transforming growth factor-beta receptor i/alk5 - Google Patents

Benzylamide derivatives as inhibitors of transforming growth factor-beta receptor i/alk5

Info

Publication number
ZA202205149B
ZA202205149B ZA2022/05149A ZA202205149A ZA202205149B ZA 202205149 B ZA202205149 B ZA 202205149B ZA 2022/05149 A ZA2022/05149 A ZA 2022/05149A ZA 202205149 A ZA202205149 A ZA 202205149A ZA 202205149 B ZA202205149 B ZA 202205149B
Authority
ZA
South Africa
Prior art keywords
diseases
compounds
alk5
growth factor
transforming growth
Prior art date
Application number
ZA2022/05149A
Other languages
English (en)
Inventor
Artal Ramón Bosser
Casal Begoña Pampín
Laria Julio Castro Palomino
Original Assignee
Origo Biopharma S L
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Origo Biopharma S L filed Critical Origo Biopharma S L
Publication of ZA202205149B publication Critical patent/ZA202205149B/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
ZA2022/05149A 2019-11-28 2022-05-10 Benzylamide derivatives as inhibitors of transforming growth factor-beta receptor i/alk5 ZA202205149B (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP19383057 2019-11-28
PCT/EP2020/083566 WO2021105317A1 (en) 2019-11-28 2020-11-27 Benzylamide derivatives as inhibitors of transforming growth factor-beta receptor i/alk5

Publications (1)

Publication Number Publication Date
ZA202205149B true ZA202205149B (en) 2025-06-25

Family

ID=68808255

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA2022/05149A ZA202205149B (en) 2019-11-28 2022-05-10 Benzylamide derivatives as inhibitors of transforming growth factor-beta receptor i/alk5

Country Status (15)

Country Link
US (2) US12297186B2 (cg-RX-API-DMAC7.html)
EP (1) EP4065572A1 (cg-RX-API-DMAC7.html)
JP (2) JP7808032B2 (cg-RX-API-DMAC7.html)
CN (1) CN114787145B (cg-RX-API-DMAC7.html)
AR (1) AR120578A1 (cg-RX-API-DMAC7.html)
AU (1) AU2020394531B2 (cg-RX-API-DMAC7.html)
BR (1) BR112022010251A2 (cg-RX-API-DMAC7.html)
CA (1) CA3160963A1 (cg-RX-API-DMAC7.html)
ES (1) ES3029608T1 (cg-RX-API-DMAC7.html)
IL (1) IL293388B2 (cg-RX-API-DMAC7.html)
MX (1) MX2022005843A (cg-RX-API-DMAC7.html)
PH (1) PH12022551177A1 (cg-RX-API-DMAC7.html)
SA (1) SA522432749B1 (cg-RX-API-DMAC7.html)
WO (1) WO2021105317A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA202205149B (cg-RX-API-DMAC7.html)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3978487A1 (en) 2020-09-30 2022-04-06 Origo Biopharma, S.L. 2-(3-pyridin-2-yl-4-quinolin-4-yl-pyrazol-1-yl)-acetamide derivatives as inhibitors of transforming growth factor-beta receptor i/alk5
AU2025225502A1 (en) 2024-02-22 2026-07-30 Agomab Spain S.L.U. Crystalline phase forms of a benzylamide derivative
WO2026082960A1 (en) 2024-10-18 2026-04-23 Agomab Therapeutics Nv 1,5-naphtyridine and quinoline based inhibitors of alk5
WO2026082968A1 (en) 2024-10-18 2026-04-23 Agomab Therapeutics Nv Novel compounds
CN122036718A (zh) * 2026-01-30 2026-05-15 安炎达医药技术(广州)有限公司 一种alk5抑制剂及其制备方法和应用

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3621540A1 (de) 1986-06-27 1988-01-07 Basf Ag Chinolinderivate, verfahren zu ihrer herstellung, diese enthaltende mikrobizide und ihre verwendung zur bekaempfung von bakterien und pilzen
ATE291020T1 (de) * 2001-02-02 2005-04-15 Smithkline Beecham Corp Pyrazolderivate gegen tgf überexprimierung
WO2004026306A2 (en) 2002-09-18 2004-04-01 Pfizer Products Inc. Pyrazole derivatives as transforming growth factor (tgf) inhibitors
WO2004026302A1 (en) * 2002-09-19 2004-04-01 Eli Lilly And Company Methods of inhibiting tgf beta with substituted pyrazoles
CL2004000234A1 (es) * 2003-02-12 2005-04-15 Biogen Idec Inc Compuestos derivados 3-(piridin-2-il)-4-heteroaril-pirazol sustituidos, antagonistas de aik5 y/o aik4; composicion farmaceutica y uso del compuesto en el tratamiento de desordenes fibroticos como esclerodermia, lupus nefritico, cicatrizacion de herid
CN102056907B (zh) 2008-04-04 2014-12-31 武田药品工业株式会社 杂环衍生物及其用途
US8937150B2 (en) 2009-06-11 2015-01-20 Abbvie Inc. Anti-viral compounds
WO2011076725A1 (en) 2009-12-21 2011-06-30 Bayer Cropscience Ag Thienylpyri (mi) dinylazole and their use for controlling phytopathogenic fungi
RU2612958C2 (ru) * 2011-07-13 2017-03-14 Ск Кемикалз Ко., Лтд. 2-пиридилзамещенные имидазолы в качестве ингибиторов alk5 и/или alk4
US11021468B2 (en) * 2015-04-01 2021-06-01 Rigel Pharmaceuticals, Inc. TGF-ß inhibitors
WO2016172631A2 (en) 2015-04-24 2016-10-27 President And Fellows Of Harvard College Substrate selective inhibitors of insulin-degrading enzyme (ide) and uses thereof
KR102434226B1 (ko) * 2016-06-30 2022-08-19 한미약품 주식회사 Alk5 억제제로서의 신규 피라졸 유도체 및 이의 용도
JP2021518855A (ja) 2018-03-02 2021-08-05 ユニヴェルシテ ド ローザンヌ Wntシグナル伝達経路阻害剤としてのピラゾール誘導体
US11945803B2 (en) 2018-08-07 2024-04-02 Tosk, Inc. Modulators of RAS GTPase
CN110433164A (zh) * 2019-08-15 2019-11-12 南开大学 TGF-beta受体分子抑制剂在治疗小鼠动物模型中急性髓系白血病的应用
EP3978487A1 (en) 2020-09-30 2022-04-06 Origo Biopharma, S.L. 2-(3-pyridin-2-yl-4-quinolin-4-yl-pyrazol-1-yl)-acetamide derivatives as inhibitors of transforming growth factor-beta receptor i/alk5

Also Published As

Publication number Publication date
SA522432749B1 (ar) 2025-05-12
AU2020394531B2 (en) 2026-06-25
US12297186B2 (en) 2025-05-13
JP7808032B2 (ja) 2026-01-28
CN114787145B (zh) 2024-03-26
KR20220107180A (ko) 2022-08-02
WO2021105317A1 (en) 2021-06-03
IL293388B1 (en) 2025-12-01
EP4065572A1 (en) 2022-10-05
ES3029608T1 (en) 2025-06-24
IL293388B2 (en) 2026-04-01
BR112022010251A2 (pt) 2022-09-06
US20250333395A1 (en) 2025-10-30
JP2025163046A (ja) 2025-10-28
AU2020394531A1 (en) 2022-06-09
AR120578A1 (es) 2022-02-23
US20230025933A1 (en) 2023-01-26
JP2023504795A (ja) 2023-02-07
PH12022551177A1 (en) 2024-02-05
MX2022005843A (es) 2022-07-19
IL293388A (en) 2022-07-01
CA3160963A1 (en) 2021-06-03
CN114787145A (zh) 2022-07-22

Similar Documents

Publication Publication Date Title
PH12022551177A1 (en) Benzylamide derivatives as inhibitors of transforming growth factor-beta receptor i/alk5
GEP20237561B (en) Protein tyrosine phosphatase inhibitors
MX2022010011A (es) Inhibidores de prmt5 novedosos.
CR20230310A (es) Inhibidores de prmt5
MX2023009222A (es) Inhibidores tricíclicos-amido-bicíclicos de prmt5.
PH12021550674A1 (en) Protein tyrosine phosphatase inhibitors
MX2023005636A (es) Inhibidores de bcl6 derivados de bencimidazolona.
GEAP202515818A (en) Amino quinazoline derivatives as p2x3 inhibitors
EP4371562A3 (en) 2-quinolone derived inhibitors of bcl6
MX2023000521A (es) Derivados de piridazinil-amino como inhibidores de el receptor tipo i de factor de crecimiento transformante beta (alk5).
PH12021551304A1 (en) Tyrosine kinase inhibitors, compositions and methods there of
PH12021552375A1 (en) Novel compounds and pharmaceutical compositions thereof for the treatment of inflammatory disorders
MY202753A (en) Griseofulvin compound and pharmaceutical use thereof
MX2023013683A (es) Compuestos de isoxazolilo fusionados como inhibidores de lisina acetiltransferasa 6a (kat6a).
EP4480485A3 (en) Protein kinase inhibitors and uses thereof for the treatment of diseases and conditions
PH12022552727A1 (en) COMPOUNDS AND COMPOSITIONS FOR INHIBITING THE ACTIVITY OF HIF2a AND THEIR METHODS OF USE
MX2024008558A (es) Derivados de piridazinil amino como inhibidores del receptor del factor de crecimiento transformante b de tipo i (alk5).
PH12021552377A1 (en) Novel compounds and pharmaceutical compositions thereof for the treatment of inflammatory disorders
PH12022500015A1 (en) Ccr6 receptor modulators
MX2022004878A (es) Derivados de n-(heteroaril)quinazolin-2-amina a manera de inhibidores de lrrk2, composiciones farmaceuticas y usos de los mismos.
MX2025001865A (es) Compuestos de piridinona sustituida como inhibidores de cbl-b
PH12021550143A1 (en) Pyridopyrimidines as histamine h4-receptor inhibitors
MX2024003930A (es) Moduladores de trpml, sus composiciones y metodos de uso.
PH12021552376A1 (en) Novel compounds and pharmaceutical compositions thereof for the treatment of inflammatory disorders
EA201070898A1 (ru) Новое производное хиназолин-2,4-диона и лекарственные композиции на его основе для профилактики и лечения заболевания, обусловленного поражением черепно-мозгового нерва